This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Stanford Graduate School of Business (USA)
-
Novartis’ Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries’ Health Care Systems - Teaching Note
Chess, R; Luthre, JTeaching Note SGSB-E489TN-EEntrepreneurshipInternational healthcare and reimbursement systems underwent a radical transformation in the 2000s, resulting from growing financial pressures incited by economic depression and a steady rise in healthcare spending. This phenomenon was most pronounced in the United States, where the health-spending share of GDP rose from five percent in 1960 to 17.9 percent in 2011. In Organization for Economic Co-operation and Development (OECD) countries on a...Starting at €0.00
-
Impact America Fund: Challenges of New Fund Formation
Krauel, Patel, H; Ewald, C; Foroughi, JCase SGSB-SI139-EBusiness Ethics and Corporate Social Responsibility, Innovation and ChangeIn July 2013, Kesha Cash transitioned out of her stable role as co-founder of and fund manager for Jalia Ventures (“Jalia”), an initiative investing in early-stage mission driven “businesses operated by entrepreneurs of color,” to launch her own impact venture fund focused on underserved communities. Because Jalia had been funded and supported by Serious Change, L.P., a global impact investment fund, Cash was new to the process of fund formation...Starting at €8.20
-
Novartis’ Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries’ Health Care Systems
Chess, R; Luthre, JCase SGSB-E489-EEntrepreneurshipInternational healthcare and reimbursement systems underwent a radical transformation in the 2000s, resulting from growing financial pressures incited by economic depression and a steady rise in healthcare spending. This phenomenon was most pronounced in the United States, where the health-spending share of GDP rose from five percent in 1960 to 17.9 percent in 2011. In Organization for Economic Co-operation and Development (OECD) countries on a...Starting at €8.20